At Astellas, we are dedicated to improving the health of people around the world
by developing innovative and reliable therapies that allow patients and physicians
to take the next steps in tackling hard-to-treat diseases. Today we are striving
to be at the forefront of the war against cancer by arming patients with an arsenal
of weapons and tools to help them manage their disease and live productive lives.
Innovative solutions, dynamic partnerships, a distinctive position in the oncology
Astellas is focused on becoming a global category leader in oncology by developing
a world-class oncology platform based on innovative, research-driven solutions and
dynamic partnerships. With this unrelenting commitment to research and development
at our core, we believe that our success will depend on our unique ability to discover
and develop molecularly targeted therapies and precision medicines that truly revolutionize
the methods used to treat cancer patients.
Oncology research facilities include the recently completed Tsukuba Research Center,
a 1.5 million-square-foot drug discovery research facility in Tsukuba City, Japan.
Astellas also has broken ground on a new 160,000-square-foot, state-of-the-art facility
in Santa Monica, Cal., which will be the new home of Agensys,
Inc., an affiliate of Astellas Pharma Inc., in early 2013.
This information is intended for U.S. residents only.
A Robust Pipeline of Investigational Agents
Astellas is committed to achieving global category leadership in oncology through
a three-tiered approach that includes (1) research and development that targets
the fundamental aspects of tumor biology, (2) strategic partnerships such as our
acquisition of OSI Pharmaceuticals in 2010, and (3) our existing expertise in urology
and supportive care. Through these efforts, Astellas is quickly developing a robust
pipeline of investigational agents.